Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin.
Overactive bladder (OAB) is a difficult condition to live with and is very costly to the community. OAB affects 16% of the adult population and rises with increasing age. We describe the necessary steps in evaluation and behavioral therapy prior to initiating medical therapy. There are several medications that have been used for the treatment of patients who suffer from OAB. This manuscript discusses the popular agents used for OAB, with a focus on the recent clinical trials on darifenacin.
Chughtai
Bilal
B
Albany Medical College, Division of Urology, Albany, NY, USA.
Levin
Robert
R
De
Elise
E
D000368:Aged; D000375:Aging; D001572:Benzofurans / Q000627:therapeutic use*; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000627:therapeutic use*; D043587:Receptor, Muscarinic M3; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology; D014563:Urodynamics / Q000187:drug effects
D001572:Benzofurans; D018727:Muscarinic Antagonists; D011759:Pyrrolidines; D043587:Receptor, Muscarinic M3; C101207:darifenacin